Anand Gaurav

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7678631/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATION
1	Structure-based three-dimensional pharmacophores as an alternative to traditional methodologies. Journal of Receptor, Ligand and Channel Research, 0, , 27.	0.7	29
2	Polymerases of Coronaviruses. , 2019, , 271-300.		22
3	Pharmacophore modeling, 3DQSAR, and docking-based design of polysubstituted quinolines derivatives as inhibitors of phosphodiesterase 4, and preliminary evaluation of their anti-asthmatic potential. Medicinal Chemistry Research, 2014, 23, 5008-5030.	1.1	21
4	An Overview on Synthetic Methodologies and Biological Activities of Pyrazoloquinolines. Mini-Reviews in Medicinal Chemistry, 2010, 10, 1194-1210.	1.1	16
5	Synthesis of 2â€(2â€oxoâ€2 <i>H</i> â€chromenâ€4â€yl)acetamides as potent acetylcholinesterase inhibitors and molecular insights into binding interactions. Archiv Der Pharmazie, 2019, 352, e1800310.	2.1	15
6	Structure-based design of selective phosphodiesterase 4B inhibitors based on ginger phenolic compounds. Journal of Biomolecular Structure and Dynamics, 2017, 35, 2910-2924.	2.0	14
7	In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes. Pharmacia, 2020, 67, 363-371.	0.4	14
8	<i>In Silico</i> Investigation of Flavonoids as Potential Trypanosomal Nucleoside Hydrolase Inhibitors. Advances in Bioinformatics, 2015, 2015, 1-10.	5.7	13
9	Docking based screening and molecular dynamics simulations to identify potential selective PDE4B inhibitor. Heliyon, 2020, 6, e04856.	1.4	12
10	Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system. Molecular Diversity, 2023, 27, 959-985.	2.1	11
11	Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia. Current Topics in Medicinal Chemistry, 2020, 20, 2404-2421.	1.0	8
12	3D-QSAR studies of 4-quinolone derivatives as high-affinity ligands at the benzodiazepine site of brain GABAA receptors. Medicinal Chemistry Research, 2011, 20, 192-199.	1.1	7
13	Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening. Computational Biology and Chemistry, 2018, 77, 52-63.	1.1	6
14	Structure-based discovery and bio-evaluation of a cyclopenta[4,5]thieno[2,3- <i>d</i>]pyrimidin-4-one as a phosphodiesterase 10A inhibitor. RSC Advances, 2022, 12, 1576-1591.	1.7	6
15	Identification of dual inhibitor of phosphodiesterase 1B/10A using structure-based drug design approach. Journal of Molecular Liquids, 2021, 342, 117485.	2.3	5
16	Protein-Protein Interactions of Phosphodiesterases. Current Topics in Medicinal Chemistry, 2019, 19, 555-564.	1.0	5
17	Quantitative structure–activity relationship and design of polysubstituted quinoline derivatives as inhibitors of phosphodiesterase 4. Medicinal Chemistry Research, 2012, 21, 3087-3103.	1.1	4
18	Evaluation of the Therapeutic Effect of the Traditional Herbal Medicine Atrifil and Oshagh Gum on Testosterone-Induced Benign Prostatic Hyperplasia in Wistar Rats. Advances in Urology, 2022, 2022, 1-14.	0.6	4

Anand Gaurav

#	Article	IF	CITATIONS
19	3D QSAR Pharmacophore, CoMFA and CoMSIA Based Design and Docking Studies on Phenyl Alkyl Ketones as Inhibitors of Phosphodiesterase 4. Medicinal Chemistry, 2012, 8, 894-912.	0.7	3
20	Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors. Iranian Journal of Pharmaceutical Research, 2017, 16, 910-923.	0.3	3
21	QSAR Studies on 4-Quinolone Derivatives as High-Affinity Ligands at the Benzodiazepine Site of Brain GABAA Receptors. Medicinal Chemistry, 2009, 5, 353-358.	0.7	2
22	Exploring the Structure Activity Relationships of Imidazole Containing Tetrahydrobenzodiazepines as Farnesyltransferase Inhibitors: A QSAR Study. Letters in Drug Design and Discovery, 2011, 8, 506-515.	0.4	2
23	NOS Inhibitors: Structure, Biological Activity and Mechanism of Action. Current Enzyme Inhibition, 2016, 12, 16-29.	0.3	1
24	In Silico Investigations on the Probable Macromolecular Drug Targets Involved in the Anti-Schizophrenia Activity of Terminalia bellerica. Letters in Organic Chemistry, 2022, 19, 83-92.	0.2	1
25	Computational Alanine Scanning Mutagenesis: Characterizing the hotspots of ILK-Ankyrin Repeat and PINCH1 Complex. , 0, , .		1
26	Pharmacophore Modelling and Virtual Screening Studies for the Discovery of Potential Natural Products Based PDE1B Inhibitor Lead Compounds. Central Nervous System Agents in Medicinal Chemistry, 2021, 21, 195-204.	0.5	1
27	Computational Approaches in the Development of Phosphodiesterase Inhibitors. , 0, , .		0
28	Identifying the Structural Features of Pyrazolo[4,3-c]Quinoline-3-ones as Inhibitors of Phosphodiesterase 4: An Exploratory CoMFA and CoMSIA Study. Current Enzyme Inhibition, 2013, 9, 106-116.	0.3	0
29	Syntheses, characterization, and evaluation of novel non-carboxylic analogues of Gemfibrozil: a bioisosteric approach. Journal of Chinese Pharmaceutical Sciences, 2017, 26, .	0.4	Ο